businesspress24.com - Dynavax Appoints Natale Ricciardi to Its Board of Directors
 

Dynavax Appoints Natale Ricciardi to Its Board of Directors

ID: 1243384

(firmenpresse) - BERKELEY, CA -- (Marketwired) -- 07/08/13 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the appointment of Natale ("Nat") Ricciardi to its Board of Directors. Mr. Ricciardi spent his entire 39-year biopharmaceutical career at Pfizer Inc, retiring in 2011 as a member of the Pfizer Executive Leadership Team after holding the positions of President, Pfizer Global Manufacturing, and Senior Vice President of Pfizer Inc. In addition to his corporate leadership role, Nat was directly responsible for all of Pfizer's internal and external supply organization, a global enterprise that grew to more than 100 manufacturing facilities supplying small and large molecule pharmaceuticals, vaccines, consumer, nutrition and animal health products.

Mr. Ricciardi maintained responsibility for global manufacturing activities from 2004 through 2011. Previously, from 1999 to 2004, he had oversight for Pfizer's US manufacturing operations and from 1995 to 1999 was Vice President of Manufacturing for Pfizer's Animal Health Group.

"On behalf of Dynavax, we are delighted to welcome Nat to the Board. His experienced leadership, particularly in global manufacturing, will provide valuable insight to the Company and we look forward to his contributions," said Arnold Oronsky, Chairman of the Board.

Mr. Ricciardi served on the boards of the National Association of Manufacturers and Mediacom Communications Corporation until its privatization in 2011. He is currently a member of the board of the 21st Century Foundation of The City College of New York. Nat earned a degree in Chemical Engineering from The City College of New York and an MBA in Finance and International Business from Fordham University.



Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Dynavax's lead product candidate is HEPLISAV™, a Phase 3 investigational adult hepatitis B vaccine. For more information visit .







Michael Ostrach
Vice President and Chief Business Officer
510-665-7257


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Type2Defense(TM) Available on the Amazon Healthy Provisions Online Store
Sernova Receives Patent Allowance for Therapeutic Immune Privileged Cell Technologies
Bereitgestellt von Benutzer: Marketwired
Datum: 08.07.2013 - 14:00 Uhr
Sprache: Deutsch
News-ID 1243384
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

BERKELEY, CA


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 95 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Dynavax Appoints Natale Ricciardi to Its Board of Directors
"
steht unter der journalistisch-redaktionellen Verantwortung von

Dynavax Technologies (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Dynavax Technologies



 

Who is online

All members: 10 565
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 84


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.